跳至主要内容
临床试验/NCT01177709
NCT01177709终止不适用

Evaluation of the Efficacy of Metformin for Weight Loss and Metabolic Effects In Overweight Psychiatric Patients Treated With Antipsychotic Medication

Nathan Kline Institute for Psychiatric Research1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2008年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
12
试验地点
1
主要终点
Weight (wt) in Pounds (Lbs)..

研究概览

简要总结

Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.

详细描述

Patients who had gained more than 10 lbs of weight in the last 3 months or had BMI of 35 or greater were treated with metformin up to 2500 mg/day in an open label study of up to 3 months time. Changes in weight and glucose measures were recorded.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients will be 18-70 years of age;
  • Currently hospitalized or an outpatient at MPC;
  • BMI ≥ 35 or excessive recent weight gain ( > than 10 lb weight gain in the past 3 months);
  • Patients will have a diagnosis of schizophrenia or schizoaffective disorder or bipolar disorder.

排除标准

  • Age below 18 or over 70;
  • Patient is currently already treated with metformin.

研究组 & 干预措施

Metformin

Experimental

干预措施: Metformin (Drug)

结局指标

主要结局

Weight (wt) in Pounds (Lbs)..

时间窗: baseline, 4 weeks, 8 weeks, 12 weeks

Patients weight in pounds

次要结局

  • Glucose Levels(baseline, 4 weeks, 8 weeks, 12 weeks)
  • Insulin Level(baseline, 4 weks, 8 weeks, 12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Robert C. Smith MD PhD

Research Psychiatrist-Principal investigator

Nathan Kline Institute for Psychiatric Research

研究点 (1)

Loading locations...

相似试验